CA2625553C - Method for treating neuronal and non-neuronal pain - Google Patents

Method for treating neuronal and non-neuronal pain Download PDF

Info

Publication number
CA2625553C
CA2625553C CA2625553A CA2625553A CA2625553C CA 2625553 C CA2625553 C CA 2625553C CA 2625553 A CA2625553 A CA 2625553A CA 2625553 A CA2625553 A CA 2625553A CA 2625553 C CA2625553 C CA 2625553C
Authority
CA
Canada
Prior art keywords
pain
neural
alkyl
inhibitors
neuronal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2625553A
Other languages
English (en)
French (fr)
Other versions
CA2625553A1 (en
Inventor
Min Zhuo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Forever Cheer Holding Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2625553A1 publication Critical patent/CA2625553A1/en
Application granted granted Critical
Publication of CA2625553C publication Critical patent/CA2625553C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2625553A 2005-10-14 2006-10-13 Method for treating neuronal and non-neuronal pain Active CA2625553C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US72671805P 2005-10-14 2005-10-14
US60/726,718 2005-10-14
PCT/CA2006/001687 WO2007041863A1 (en) 2005-10-14 2006-10-13 Method for treating neuronal and non-neuronal pain

Publications (2)

Publication Number Publication Date
CA2625553A1 CA2625553A1 (en) 2007-04-19
CA2625553C true CA2625553C (en) 2014-03-11

Family

ID=37942274

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2625553A Active CA2625553C (en) 2005-10-14 2006-10-13 Method for treating neuronal and non-neuronal pain

Country Status (6)

Country Link
US (1) US8124599B2 (https=)
EP (1) EP1948182B1 (https=)
JP (1) JP5404045B2 (https=)
CN (1) CN1947717B (https=)
CA (1) CA2625553C (https=)
WO (1) WO2007041863A1 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1947717B (zh) 2005-10-14 2012-09-26 卓敏 选择性抑制腺苷酸环化酶1的化合物在制备用于治疗神经性疼痛和炎性疼痛的药物中的应用
LT1976828T (lt) 2005-12-29 2017-04-25 Celtaxsys, Inc. Diamino dariniai, kaip leukotrieno a4 hidrolazės inhibitoriai
AR065372A1 (es) 2007-02-19 2009-06-03 Smithkline Beecham Corp Derivados de purina
UA103195C2 (uk) 2008-08-11 2013-09-25 Глаксосмитклайн Ллк Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань
EP2326646B1 (en) 2008-08-11 2013-07-31 GlaxoSmithKline LLC Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases
BRPI0917013A2 (pt) 2008-08-11 2016-02-16 Glaxosmithkline Llc métodos para tratar doenças alérgicas e outras condições inflamatórias, e para tratar ou prevenir doença, composto, composição farmacêutica, e, uso de um composto
US8802684B2 (en) 2008-08-11 2014-08-12 Glaxosmithkline Llc Adenine derivatives
WO2010088924A1 (en) 2009-02-06 2010-08-12 Telormedix Sa Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
WO2011098451A1 (en) 2010-02-10 2011-08-18 Glaxosmithkline Llc Purine derivatives and their pharmaceutical uses
US9050319B2 (en) 2010-04-30 2015-06-09 Telormedix, Sa Phospholipid drug analogs
AU2011247358B2 (en) 2010-04-30 2014-10-30 Urogen Pharma Ltd. Phospholipid drug analogs
HRP20181667T1 (hr) 2011-07-22 2018-12-14 Glaxosmithkline Llc Pripravak
EA026354B1 (ru) 2012-08-24 2017-03-31 ГЛАКСОСМИТКЛАЙН ЭлЭлСи Пиразолопиримидиновые соединения
AU2013348217B2 (en) 2012-11-20 2016-10-06 Glaxosmithkline Llc Novel compounds
BR112015011439A2 (pt) 2012-11-20 2017-07-11 Glaxosmithkline Llc composto, composição farmacêutica, composição de vacina, e, uso de um composto
EA028480B1 (ru) 2012-11-20 2017-11-30 ГЛАКСОСМИТКЛАЙН ЭлЭлСи Новые соединения
AU2014249168B2 (en) 2013-03-12 2018-07-12 Celltaxis, Llc Methods of inhibiting leukotriene A4 hydrolase
BR112015022864A8 (pt) 2013-03-14 2019-11-26 Celtaxsys Inc composto, composição farmacêutica e uso dos mesmos
CA2906035A1 (en) 2013-03-14 2014-09-25 Celtaxsys, Inc. Inhibitors of leukotriene a4 hydrolase
WO2014152536A2 (en) 2013-03-14 2014-09-25 Celtaxsys, Inc. Inhibitors of leukotriene a4 hydrolase
TWI731317B (zh) 2013-12-10 2021-06-21 美商健臻公司 原肌球蛋白相關之激酶（ｔｒｋ）抑制劑
EA201791336A1 (ru) 2014-12-18 2017-10-31 Джензим Корпорейшн Фармацевтические составы на основе ингибиторов тропомиозин-родственных киназ (trk)
JP6902336B2 (ja) * 2016-08-01 2021-07-14 永展国際有限公司Ｆｏｒｅｖｅｒ Ｃｈｅｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｌｉｍｉｔｅｄ ５−［２−［（６−アミノ）−９ｈ−プリン−９−イル］エチルアミノ］−１−ペンタノール多結晶体
JP7332841B2 (ja) * 2017-05-20 2023-08-24 永展控股有限公司 疼痛を治療するための薬用組成物
ES3014615T3 (en) 2018-05-31 2025-04-23 Celltaxis Llc Method of reducing pulmonary exacerbations in respiratory disease patients
CN108853110B (zh) * 2018-08-24 2020-07-28 江苏理工学院 一种化合物a8作为组蛋白甲基转移酶nsd3活性抑制剂及其应用
CN114931561B (zh) * 2022-05-25 2024-02-02 青岛永展医药科技有限公司 一种治疗慢性痛的胶囊组合物及其制备方法
CN118526502A (zh) * 2024-07-24 2024-08-23 浙江永展医药科技有限公司 腺苷酸环化酶抑制剂用于制备治疗围手术期疼痛药物的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2844577A (en) * 1958-07-22 Certificate of correction
US2691654A (en) 1952-06-11 1954-10-12 Buroughs Wellcome & Co U S A I Amino heterocycles and method of making
US3691654A (en) * 1969-05-29 1972-09-19 Gen Electric Metal foil lead manufacture
US4189485A (en) * 1977-08-23 1980-02-19 Takeda Chemical Industries, Ltd. Purine derivatives
JPS6058726B2 (ja) * 1977-10-05 1985-12-21 日本臓器製薬株式会社 プリン誘導体を有効成分として含有する抗アレルギ−，鎮痛，鎮静剤
JPS61171423A (ja) 1985-01-24 1986-08-02 Advance Res & Dev Co Ltd 抗う蝕乃至抗歯周症剤
GB0100623D0 (en) 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds IV
AU2002303023A1 (en) 2002-06-05 2003-12-22 Metabolic Engineering Laboratories Co., Ltd. Signals and molecular species involved in senescence
US20040013669A1 (en) 2002-06-12 2004-01-22 Feng Wei Method for treating persistent pain and identifying compounds to treat persistent pain
WO2004037159A2 (en) * 2002-10-23 2004-05-06 Obetherapy Biotechnology Compounds, compositions and methods for modulating fat metabolism
RU2233842C1 (ru) * 2003-01-13 2004-08-10 Петров Владимир Иванович Производные пурина, обладающие противовирусной активностью
GB0305149D0 (en) * 2003-03-07 2003-04-09 Cambridge Biotechnology Ltd Compounds for the treatment of pain
US20080221060A1 (en) 2004-03-05 2008-09-11 Martyn Pritchard Therapeutic Compounds
WO2005092306A1 (en) 2004-03-11 2005-10-06 The General Hospital Corporation Methods and compositions for modulating opioid tolerance and chronic pain
WO2006002422A2 (en) * 2004-06-24 2006-01-05 Novartis Vaccines And Diagnostics Inc. Compounds for immunopotentiation
CN1947717B (zh) 2005-10-14 2012-09-26 卓敏 选择性抑制腺苷酸环化酶1的化合物在制备用于治疗神经性疼痛和炎性疼痛的药物中的应用

Also Published As

Publication number Publication date
JP5404045B2 (ja) 2014-01-29
CA2625553A1 (en) 2007-04-19
CN1947717A (zh) 2007-04-18
US20090233922A1 (en) 2009-09-17
US8124599B2 (en) 2012-02-28
CN1947717B (zh) 2012-09-26
EP1948182A4 (en) 2009-08-19
EP1948182A1 (en) 2008-07-30
WO2007041863A1 (en) 2007-04-19
EP1948182B1 (en) 2012-12-12
JP2009511508A (ja) 2009-03-19

Similar Documents

Publication Publication Date Title
CA2625553C (en) Method for treating neuronal and non-neuronal pain
Bruchas et al. Stress-induced p38 mitogen-activated protein kinase activation mediates κ-opioid-dependent dysphoria
Bracey et al. The Nlrp3 inflammasome promotes myocardial dysfunction in structural cardiomyopathy through interleukin‐1β
US10973913B2 (en) JAK inhibitors and uses thereof
Abdala et al. Correction of respiratory disorders in a mouse model of Rett syndrome
Navegantes et al. Catecholamines inhibit Ca2+-dependent proteolysis in rat skeletal muscle through β2-adrenoceptors and cAMP
Quirk et al. Prefrontal mechanisms in extinction of conditioned fear
Ringer et al. Development of a xylazine constant rate infusion with or without butorphanol for standing sedation of horses
Boye et al. Disruption of dopaminergic neurotransmission in nucleus accumbens core inhibits the locomotor stimulant effects of nicotine and D-amphetamine in rats
Manahan‐Vaughan et al. Rescue of hippocampal LTP and learning deficits in a rat model of psychosis by inhibition of glycine transporter‐1 (GlyT1)
Doyle et al. Activation of sphingosine-1-phosphate receptor 1 in the spinal cord produces mechanohypersensitivity through the activation of inflammasome and IL-1β pathway
Stone et al. Emerging evidence for a central epinephrine-innervated α1-adrenergic system that regulates behavioral activation and is impaired in depression
Kryukov et al. Status epilepticus alters hippocampal long-term synaptic potentiation in a rat lithium-pilocarpine model
Hashizume et al. High molecular weight hyaluronic acid inhibits IL-6-induced MMP production from human chondrocytes by up-regulating the ERK inhibitor, MKP-1
Foulstone et al. Insulin‐like growth factors (IGF‐I and IGF‐II) inhibit C2 skeletal myoblast differentiation and enhance TNFα‐induced apoptosis
JP6243996B2 (ja) Ｂｃａｔ１阻害剤を使用する治療方法
Salvatore et al. Modulation of nigral dopamine signaling mitigates parkinsonian signs of aging: evidence from intervention with calorie restriction or inhibition of dopamine uptake
Leszkowicz et al. Noradrenaline‐induced enhancement of oscillatory local field potentials in the mouse accessory olfactory bulb does not depend on disinhibition of mitral cells
d'Mello et al. Dimethylarginine dimethylaminohydrolase 1 is involved in spinal nociceptive plasticity
EP2029139B1 (en) Use of a p38 kinase inhibitor for treating psychiatric disorders
Taksande et al. Acute orexigenic effect of agmatine involves interaction between central α2-adrenergic and GABAergic receptors
US20100260772A1 (en) Methods for treating or preventing diseases associated with low bone mass
Colditz et al. Effect of the non‐steroidal anti‐inflammatory drug, carprofen, on weaned sheep following non‐surgical mulesing by intradermal injection of cetrimide
Lambert et al. Suppression by eletriptan of the activation of trigeminovascular sensory neurons by glyceryl trinitrate
Monti et al. A study of the brain structures involved in the acute effects of fluoxetine on REM sleep in the rat

Legal Events

Date Code Title Description
EEER Examination request
MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 19TH ANNIV.) - STANDARD

Year of fee payment: 19

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250505

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250505